PharmacoEconomics

Acknowledgement
pp. 1169-1171(3)
Author: Adis International Limited,

Do Pharmacogenomic Tests Provide Value to Policy Makers?
pp. 1173-1177(5)
Authors: Ya-Chen Tina Shih,; Pusztai, Lajos

Letter From the Commissioner's Office at the US FDA
pp. 1179-1179(1)
Author: Vernon, John A.

Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis
pp. 1181-1197(17)
Authors: Urdahl, Hege; Manca, Andrea; Sculpher, Mark J.

Generic Health-Related Quality-of-Life Assessment in Children and Adolescents: Methodological Considerations
pp. 1199-1220(22)
Authors: Ravens-Sieberer, Ulrike; Erhart, Michael; Wille, Nora; Wetzel, Ralf; Nickel, Jennifer; Bullinger, Monika

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
pp. 1221-1232(12)
Authors: Spalding, James R.; Hay, Joel

Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia
pp. 1233-1248(16)
Authors: Yu, Wei; Ren, Xinhua S.; Lee, Austin F.; Herz, Lawrence; Huang, Yu-Hui; Kazis, Lewis E.

Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension
pp. 1249-1272(24)
Authors: Plosker, Greg L.; Keam, Susan J.

Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
pp. 1273-1274(2)
Author: Birks, Stuart

The Authors' Reply
pp. 1275-1276(2)
Authors: Bos, J.M.; Postma, M.J.; Annemans, L.